Mydecine signs an LOI to provide The Newly Institute with psilocybin and MDMA for use in Health Canada SAP-approved psychedelics-based therapy.
Exploring the companies and themes that make up this emerging and exciting new sector
Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent
Optimi Health submits a patent application for the extraction process for its natural psilocybin extract.
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001
Better Life Pharma reports encouraging pre-clinical results for its non-hallucinogenic psychedelic analog.
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
atai Life Sciences announces Investigational New Drug (IND) clearance from the FDA for PCN-101.
Health Canada’s SAP Amendments: A Game-Changer For Psychedelic Medicine In Canada?
On January 5, 2022, Health Canada amendments to its Special Access Program has expanded access to psychedelic drug therapies. We explore the implications.
Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
Field Trip announces receiving its USPTO patent for FT-104, including composition of matter.
Wesana Health Granted US FDA Pre-IND Meeting for SANA-013
Wesana announces a pre-IND meeting with the FDA for SANA-013 in March, it's lead drug candidate for Traumatic Brain Injury.
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Awakn announces strong results from its Phase II a/b clinical trial of a ketamine-assisted therapy for Alcohol Use Disorder (AUD).
Health Canada’s New SAP Rules: A Q&A With Numinus’ Payton Nyquvest
On January 4, 2022, amendments to Health Canada's Special Access Program took effect that explicitly include access to psychedelic medicine. We asked Numinus' Payton Nyquvest to connect the dots on the impact of these new rules.
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds
Mydecine announces the use of AI to accelerate identification of drug candidates for psychedelics research.
The next big trend in mental health treatments? Psychedelic therapy.
Magic mushrooms for your well-being? If you haven't heard about psychedelics being used as a treatment for mental health disorders, this year may change that.
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines
Mindset announces a drug development agreement with Japanese-based Otsuka Pharmaceuticals, including a $5 million strategic investment in Mindset.